Key result
PCSK9 and ANGPTL3 inhibitors substantially reduce LDL-C in refractory familial hypercholesterolemia.
Why the study?
Do monoclonal antibodies (PCSK9 and ANGPTL3 inhibitors) reduce LDL-C levels in patients with familial hypercholesterolemia when conventional therapies are inadequate?
Do monoclonal antibodies (PCSK9 and ANGPTL3 inhibitors) reduce LDL-C levels in patients with familial hypercholesterolemia when conventional therapies are inadequate?
Answers are grounded in this paper and cite their sources.
PCSK9 and ANGPTL3 inhibitors are effective adjunct therapies for reducing LDL-C in familial hypercholesterolemia, though more long-term pediatric data is needed.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) conducted a review in Familial hypercholesterolemia. PCSK9 inhibitors and ANGPTL3 inhibitors was evaluated. PCSK9 and ANGPTL3 inhibitors provide meaningful LDL-C reductions in familial hypercholesterolemia when conventional therapies are inadequate, though direct evidence in pediatric patients is limited.
Synapse has enriched 10 related papers. Consider them for comparative context: